Current and emerging medications for the treatment of leishmaniasis

References

• Sundar S, Chakravarty J. Leishmaniasis: an update of current pharmacotherapy. Expert Opin Pharmacother. 2013;14(1):53–63.
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J. An update on pharmacotherapy for leishmaniasis. Expert Opin Pharmacother. 2015;16(2):237–252.
   PubMed Web of Science ®Google Scholar
• Meeting WHOEC on the C of the L, Organization WH. Control of the Leishmaniases: Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases. Geneva: World Health Organization; 2010. Vol. 949. [2010 Mar 22-26].
   Google Scholar
• Shirian S, Oryan A, Hatam GR, et al. Three Leishmania/L. species–L. infantum, L. major, L. tropica–as causative agents of mucosal leishmaniasis in Iran. Pathog Glob Health. 2013;107(5):267–272.
   PubMed Web of Science ®Google Scholar
• Alborzi A, Pouladfar GR, Moghadam AG, et al. First molecular-based detection of mucocutaneous leishmaniasis caused by Leishmania major in Iran. J Infect Dev Ctries. 2013;7(05):413–416.
   PubMedGoogle Scholar
• Magill AJ. Epidemiology of the leishmaniases. Dermatol Clin. 1995;13(3):505–523.
   PubMed Web of Science ®Google Scholar
• Pearson RD, JS, de Queiroz Sousa A. Tropical infectious diseases: principles, pathogens and practice. Philadelphia, PA: Churchill Livingstone; 1999.
   Google Scholar
• Zijlstra EE, Musa AM, Khalil EAG, et al. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis. 2003;3(2):87–98.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Post-kala-azar dermal leishmaniasis: a manual for case management and control: report of a WHO consultative meeting; 2012 July 2–3; Kolkata, India. 2013. Available from: http://www.who.int/iris/handle/10665/78608
   Google Scholar
• Ridolfo AL, Gervasoni C, Antinori S, et al. Post-kala-azar dermal leishmaniasis during highly active antiretroviral therapy in an AIDS patient infected withLeishmania infantum. J Infect. 2000;40(2):199–202.
   PubMed Web of Science ®Google Scholar
• Boumis E, Chinello P, Della Rocca C, et al. Atypical disseminated leishmaniasis resembling post-kala-azar dermal leishmaniasis in an HIV-infected patient. Int J STD AIDS. 2006;17(5):351–353.
   PubMed Web of Science ®Google Scholar
• Badirzadeh A, Mohebali M, Ghasemian M, et al. Cutaneous and post kala-azar dermal leishmaniasis caused by Leishmania infantum in endemic areas of visceral leishmaniasis, northwestern Iran 2002–2011: a case series. Pathog Glob Health. 2013;107(4):194–197.
   PubMed Web of Science ®Google Scholar
• Reithinger R, Dujardin J-C, Louzir H, et al. Cutaneous leishmaniasis. Lancet Infect Dis. 2007;7(9):581–596.
   PubMed Web of Science ®Google Scholar
• WHO | Weekly Epidemiological Record, WHO [Internet] . 2018 Nov 30, vol. 93, 48 (pp. 649–660). [cited 2018 Dec 3]. Available from: http://www.who.int/wer/2018/wer9348/en/
   Google Scholar
• WHO | Leishmaniasis and HIV coinfection. WHO [Internet]. 2014 [cited 2018 Dec 3]; Available from: http://www.who.int/leishmaniasis/burden/hiv_coinfection/burden_hiv_coinfection/en/
   Google Scholar
• Alvar J, Canavate C, Gutierrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev. 1997;10(2):298–319.
   PubMed Web of Science ®Google Scholar
• Desjeux P, Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol. 2003;97(sup1):3–15.
   PubMed Web of Science ®Google Scholar
• Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008;21(2):334–359.
   PubMed Web of Science ®Google Scholar
• Burza S, Sinha PK, Mahajan R, et al. Five-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India. Franco-Paredes C, editor. PLoS Negl Trop Dis [Internet]. 2014 Jan 2. 8(1):e2603. [cited 2018 Dec 3]. DOI:10.1371/journal.pntd.0002603
   PubMed Web of Science ®Google Scholar
• Burza S, Mahajan R, Sanz MG, et al. HIV and visceral leishmaniasis coinfection in Bihar, India: an underrecognized and underdiagnosed threat against elimination. Clin Infect Dis. 2014;59(4):552–555.
   PubMed Web of Science ®Google Scholar
• de Sousa-Gomes ML, Romero GAS, Werneck GL. Visceral leishmaniasis and HIV/AIDS in Brazil: are we aware enough? PLoS Negl Trop Dis. 2017;11(9):e0005772.
   PubMed Web of Science ®Google Scholar
• Mengesha B, Endris M, Takele Y, et al. Prevalence of malnutrition and associated risk factors among adult visceral leishmaniasis patients in Northwest Ethiopia: a cross sectional study. BMC Res Notes. 2014;7(1):75.
   PubMedGoogle Scholar
• Mengistu G, Ayele B. Visceral Lieshmaniasis and HIV co-infection in patients admitted to Gondar University Hospital, Northwest Ethiopia. Ethiop J Heal Dev. 2007;21(1):53–60.
   Google Scholar
• Sundar S, More DK, Singh MK, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis. 2000;31(4):1104–1107.
   PubMed Web of Science ®Google Scholar
• Rijal S, Chappuis F, Singh R, et al. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans R Soc Trop Med Hyg. 2003;97(3):350–354.
   PubMed Web of Science ®Google Scholar
• Ritmeijer K, Dejenie A, Assefa Y, et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis. 2006;43(3):357–364.
   PubMed Web of Science ®Google Scholar
• Diro E, Lynen L, Mohammed R, et al. High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia. PLoS Negl Trop Dis. 2014;8(5):e2875.
   PubMed Web of Science ®Google Scholar
• Tallab TM, Bahamdam KA, Mirdad S, et al. Cutaneous leishmaniasis: schedules for intralesional treatment with sodium stibogluconate. Int J Dermatol. 1996;35(8):594–597.
   PubMed Web of Science ®Google Scholar
• Sharquie KE, Al‐Talib KK, Chu AC. Intralesional therapy of cutaneous leishmaniasis with sodium stibogluconate antimony. Br J Dermatol. 1988;119(1):53–57.
   PubMed Web of Science ®Google Scholar
• Uzun S, Durdu M, Culha G, et al. Clinical features, epidemiology, and efficacy and safety of intralesional antimony treatment of cutaneous leishmaniasis: recent experience in Turkey. J Parasitol. 2004;90(4):853–859.
   PubMed Web of Science ®Google Scholar
• Ranawaka RR, Weerakoon HS. Randomized, double-blind, comparative clinical trial on the efficacy and safety of intralesional sodium stibogluconate and intralesional 7% hypertonic sodium chloride against cutaneous leishmaniasis caused by L. donovani. J Dermatolog Treat. 2010;21(5):286–293.
   PubMed Web of Science ®Google Scholar
• Bumb RA, Mehta RD, Ghiya BC, et al. Efficacy of short‐duration (twice weekly) intralesional sodium stibogluconate in treatment of cutaneous leishmaniasis in India. Br J Dermatol. 2010;163(4):854–858.
   PubMed Web of Science ®Google Scholar
• Faghihi G, Tavakoli‐Kia R. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate. Clin Exp Dermatol. 2003;28(1):13–16.
   PubMed Web of Science ®Google Scholar
• El-Safi SH, Peters W, Evans DA. Studies on the leishmaniases in the Sudan. 3. Clinical and parasitological studies on visceral and mucosal leishmaniasis. Trans R Soc Trop Med Hyg. 1991;85(4):465–470.
   PubMed Web of Science ®Google Scholar
• Firdous R, Yasinzai M, Ranja K. Efficacy of glucantime in the treatment of Old World cutaneous leishmaniasis. Int J Dermatol. 2009;48(7):758–762.
   PubMed Web of Science ®Google Scholar
• Firooz A, Khamesipour A, Ghoorchi MH, et al. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch Dermatol. 2006;142(12):1575–1579.
   PubMed Web of Science ®Google Scholar
• Zerehsaz F, Salmanpour R, Handjani F, et al. A double‐blind randomized clinical trial of a topical herbal extract (Z‐HE) vs. systemic meglumine antimoniate for the treatment of cutaneous leishmaniasis in Iran. Int J Dermatol. 1999;38(8):610–612.
   PubMed Web of Science ®Google Scholar
• Monge-Maillo B, López-Vélez R. Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis. Drugs. 2013;73(17):1889–1920.
   PubMed Web of Science ®Google Scholar
• van Griensven J, Gadisa E, Aseffa A, et al. Treatment of cutaneous leishmaniasis caused by Leishmania aethiopica: A systematic review. PLoS Negl Trop Dis. 2016;10(3):e0004495.
   PubMed Web of Science ®Google Scholar
• Brito NC, Rabello A, Cota GF. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: a systematic review. PLoS One. 2017;12(9):e0184777.
   PubMed Web of Science ®Google Scholar
• Guderian RH, Chico ME, Rogers MD, et al. Placebo controlled treatment of Ecuadorian cutaneous leishmaniasis. Am J Trop Med Hyg. 1991;45(1):92–97.
   PubMed Web of Science ®Google Scholar
• Soto J, Valda-Rodriquez L, Toledo J, et al. Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis. Am J Trop Med Hyg. 2004;71(5):577–581.
   PubMed Web of Science ®Google Scholar
• Soto J, Toledo J, Vega J, et al. efficacy of pentavalent antimony for treatment of Colombian cutaneous leishmaniasis. Am J Trop Med Hyg. 2005;72(4):421–422.
   PubMed Web of Science ®Google Scholar
• Andersen EM, Cruz-Saldarriaga M, Llanos-Cuentas A, et al. Comparison of meglumine antimoniate and pentamidine for Peruvian cutaneous leishmaniasis. Am J Trop Med Hyg. 2005;72(2):133–137.
   PubMed Web of Science ®Google Scholar
• Solomon M, Pavlotzky F, Barzilai A, et al. Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers. J Am Acad Dermatol. 2013;68(2):284–289.
   PubMed Web of Science ®Google Scholar
• Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2016;63(12):e202–64.
   PubMed Web of Science ®Google Scholar
• Arevalo J, Ramirez L, Adaui V, et al. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J Infect Dis. 2007;195(12):1846–1851.
   PubMed Web of Science ®Google Scholar
• Romero GA, Guerra MV, Paes MG, et al. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am J Trop Med Hyg. 2001;65(5):456–465.
   PubMed Web of Science ®Google Scholar
• Navin TR, Arana BA, Arana FE, et al. Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am J Trop Med Hyg. 1990;42(1):43–50.
   PubMed Web of Science ®Google Scholar
• Vargas-Gonzalez A, Canto-Lara SB, Damian-Centeno AG, et al. Response of cutaneous leishmaniasis (chiclero’s ulcer) to treatment with meglumine antimoniate in Southeast Mexico. Am J Trop Med Hyg. 1999;61(6):960–963.
   PubMed Web of Science ®Google Scholar
• Franke ED, Wignall FS, Cruz ME, et al. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann Intern Med. 1990;113(12):934–940.
   PubMed Web of Science ®Google Scholar
• Oliveira-Neto MP, Mattos M, Pirmez C, et al. Mucosal leishmaniasis (“ espundia”) responsive to low dose of N-methyl glucamine (Glucantime®) in Rio de Janeiro, Brazil. Rev Inst Med Trop Sao Paulo. 2000;42(6):321–325.
   PubMedGoogle Scholar
• Franke ED, Llanos-Cuentas A, Echevarria J, et al. Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis. Am J Trop Med Hyg. 1994;51(1):77–82.
   PubMed Web of Science ®Google Scholar
• Llanos-Cuentas A, Echevarría J, Cruz M, et al. Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. Clin Infect Dis. 1997;25(3):677–684.
   PubMed Web of Science ®Google Scholar
• Cincurá C, de Lima CMF, Machado PRL, et al. Mucosal leishmaniasis: a retrospective study of 327 cases from an endemic area of Leishmania (Viannia) braziliensis. Am J Trop Med Hyg. 2017;97(3):761–766.
   PubMed Web of Science ®Google Scholar
• Thakur CP, Singh RK, Hassan SM, et al. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg. 1999;93(3):319–323.
   PubMed Web of Science ®Google Scholar
• Mishra M, Biswas UK, Jha DN, et al. Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet. 1992;340(8830):1256–1257.
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med. 2010;362(6):504–512.
   PubMed Web of Science ®Google Scholar
• Mondal D, Alvar J, Hasnain MG, et al. Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study. Lancet Glob Heal. 2014;2(1):e51–7.
   PubMed Web of Science ®Google Scholar
• Maintz EM, Hassan M, Huda MM, et al. Introducing single dose liposomal amphotericin B for the treatment of visceral leishmaniasis in rural Bangladesh: feasibility and acceptance to patients and health staff. J Trop Med. 2014;2014:676817.
   PubMedGoogle Scholar
• Khalil EAG, Weldegebreal T, Younis BM, et al. Safety and efficacy of single dose versus multiple doses of AmBisome® for treatment of visceral leishmaniasis in Eastern Africa: a randomised trial. PLoS Negl Trop Dis. 2014;8(1):e2613.
   PubMed Web of Science ®Google Scholar
• Seaman J, Boer C, Wilkinson R, et al. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis. 1995;21(1):188–193.
   PubMed Web of Science ®Google Scholar
• Salih NA, van Griensven J, Chappuis F, et al. Liposomal amphotericin B for complicated visceral leishmaniasis (kala‐azar) in eastern Sudan: how effective is treatment for this neglected disease? Trop Med Int Heal. 2014;19(2):146–152.
   PubMed Web of Science ®Google Scholar
• Tamiru A, Tigabu B, Yifru S, et al. Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia. BMC Infect Dis. 2016;16(1):548.
   PubMedGoogle Scholar
• Gebreyohannes EA, Bhagvathula AS, Abegaz TM, et al. Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis. Infect Dis Poverty. 2018;7(1):108.
   PubMedGoogle Scholar
• Saravolatz LD, Bern C, Adler-Moore J, et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis. 2006;43(7):917–924.
   PubMed Web of Science ®Google Scholar
• Gradoni L, Gramiccia M, Scalone A. Change in human visceral leishmaniasis treatment in Italy: retrospective study of 630 patients. Parassitologia. 2004;46(1–2):199–201.
   PubMedGoogle Scholar
• Syriopoulou V, Daikos GL, Theodoridou M, et al. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis. Clin Infect Dis. 2003;36(5):560–566.
   PubMed Web of Science ®Google Scholar
• Davidson RN, Di Martino L, Gradoni L, et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis. 1996;22(6):938–943.
   PubMed Web of Science ®Google Scholar
• Freire M, Badaró F, Avelar ME, et al. Efficacy and tolerability of liposomal amphotericin B (AmBisome) in the treatment of visceral leishmaniasis in Brazil. Braz J Infect Dis. 1997;1(5):230–240.
   PubMedGoogle Scholar
• Fontoura IG, Barbosa DS, de Andrade Paes AM, et al. Epidemiological, clinical and laboratory aspects of human visceral leishmaniasis (HVL) associated with human immunodeficiency virus (HIV) coinfection: a systematic review. Parasitology. 2018;145(14):1801–1818.
   Web of Science ®Google Scholar
• Russo R, Nigro LC, Minniti S, et al. Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). J Infect. 1996;32(2):133–137.
   PubMed Web of Science ®Google Scholar
• Davidson RN, Martino LD, Gradoni L, et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. QJM An Int J Med. 1994;87(2):75–81.
   PubMedGoogle Scholar
• Montana M, Chochoi N, Monges P, et al. Liposomal amphotericin B in secondary prophylaxis of visceral leishmaniasis in HIV-infected patients: report of five clinical cases. Pathol Biol Paris. 2004;52(2):66–75.
   PubMedGoogle Scholar
• Di Masi F, Ursini T, Iannece MD, et al. Five-year retrospective Italian multicentre study of visceral leishmaniasis treatment. Antimicrob Agents Chemother. 2014;58(1):414–418.
   PubMed Web of Science ®Google Scholar
• Burza S, Mahajan R, Sinha PK, et al. Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome). PLoS Negl Trop Dis. 2014;8(8):e3053.
   PubMed Web of Science ®Google Scholar
• Sinha PK, van Griensven J, Pandey K, et al. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis. 2011;53(7):e91–8.
   PubMed Web of Science ®Google Scholar
• Távora LGF, Nogueira MB, Gomes ST. Visceral Leishmaniasis/HIV co-infection in northeast Brazil: evaluation of outcome. Brazilian J Infect Dis. 2015;19(6):651–656.
   PubMed Web of Science ®Google Scholar
• Cota GF, de Sousa MR, de Mendonça ALP, et al. Leishmania-HIV co-infection: clinical presentation and outcomes in an urban area in Brazil. PLoS Negl Trop Dis. 2014;8(4):e2816.
   PubMed Web of Science ®Google Scholar
• Ritmeijer K, Ter Horst R, Chane S, et al. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clin Infect Dis. 2011;53(12):e152–8.
   PubMed Web of Science ®Google Scholar
• López-Vélez R, Videla S, Márquez M, et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother. 2004;53(3):540–543.
   PubMed Web of Science ®Google Scholar
• Molina I, Falcó V, Crespo M, et al. Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother. 2007;60(4):837–842.
   PubMed Web of Science ®Google Scholar
• Goswami RP, Goswami RP, Basu A, et al. Protective efficacy of secondary prophylaxis against visceral leishmaniasis in human immunodeficiency virus coinfected patients over the past 10 years in eastern India. Am J Trop Med Hyg. 2017;96(2):285–291.
   PubMed Web of Science ®Google Scholar
• Zijlstra EE, Alves F, Rijal S, et al. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: a threat to the South-East Asia Region Kala-azar Elimination Programme. PLoS Negl Trop Dis. 2017;11(11):e0005877.
   PubMed Web of Science ®Google Scholar
• Den Boer M, Das AK, Akhter F, et al. Safety and Effectiveness of Short-Course AmBisome in the Treatment of Post-Kala-Azar Dermal Leishmaniasis: A Prospective Cohort Study in Bangladesh. Clin Infect Dis. 2018 Aug 16;67(5):667–675.
   PubMed Web of Science ®Google Scholar
• Guery R, Henry B, Martin-Blondel G, et al. Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: not a panacea. PLoS Negl Trop Dis. 2017;11(11):e0006094.
   PubMed Web of Science ®Google Scholar
• Wortmann G, Zapor M, Ressner R, et al. Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis. Am J Trop Med Hyg. 2010;83(5):1028–1033.
   PubMed Web of Science ®Google Scholar
• Layegh P, Rajabi O, Jafari MR, et al. Efficacy of topical liposomal amphotericin B versus intralesional meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. J Parasitol Res. 2011;2011:656523. DOI:10.1155/2011/656523.
   Google Scholar
• Solomon M, Baum S, Barzilai A, et al. Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis. J Am Acad Dermatol. 2007;56(4):612–616.
   PubMed Web of Science ®Google Scholar
• Motta JOC, Sampaio RNR. A pilot study comparing low‐dose liposomal amphotericin B with N‐methyl glucamine for the treatment of American cutaneous leishmaniasis. J Eur Acad Dermatol Venereol. 2012;26(3):331–335.
   PubMed Web of Science ®Google Scholar
• Pedras MJ, Carvalho JDP, Silva RED, et al. Mucosal leishmaniasis: the experience of a Brazilian referral center. Rev Soc Bras Med Trop. 2018;51(3):318–323.
   PubMed Web of Science ®Google Scholar
• Amato VS, Tuon FF, Camargo RA, et al. Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis? Am J Trop Med Hyg. 2011;85(5):818–819.
   PubMed Web of Science ®Google Scholar
• Rocio C, Amato VS, Camargo RA, et al. Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients. Trans R Soc Trop Med Hyg. 2014;108(3):176–178.
   PubMed Web of Science ®Google Scholar
• Machado PRL, Rosa MEA, Guimarães LH, et al. Treatment of disseminated leishmaniasis with liposomal amphotericin B. Clin Infect Dis. 2015;61(6):945–949.
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med. 2002;347(22):1739–1746.
   PubMed Web of Science ®Google Scholar
• Bhattacharya SK, Sinha PK, Sundar S, et al. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis. 2007;196(4):591–598.
   PubMed Web of Science ®Google Scholar
• Sundar S, Mondal D, Rijal S, et al. Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal–the challenges for diagnosis and treatment. Trop Med Int Heal. 2008;13(1):2–5.
   PubMed Web of Science ®Google Scholar
• Sundar S, Singh A, Rai M, et al. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis. 2012;55(4):543–550.
   PubMed Web of Science ®Google Scholar
• Burza S, Nabi E, Mahajan R, et al. One-year follow-up of immunocompetent male patients treated with miltefosine for primary visceral leishmaniasis in Bihar, India. Clin Infect Dis. 2013;57(9):1363–1364.
   PubMed Web of Science ®Google Scholar
• Rijal S, Ostyn B, Uranw S, et al. Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis. 2013;56(11):1530–1538.
   PubMed Web of Science ®Google Scholar
• Carnielli JBT, Crouch K, Forrester S, et al. A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis. EBioMedicine. 2018;36:83–91.
   PubMed Web of Science ®Google Scholar
• Dorlo TP, Rijal S, Ostyn B, et al. Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure. J Infect Dis. 2014 Jul 1;210(1):146–153.
   PubMed Web of Science ®Google Scholar
• Troya J, Casquero A, Refoyo E, et al. Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients. Scand J Infect Dis. 2008;40(1):78–80.
   PubMed Web of Science ®Google Scholar
• Ramesh V, Katara GK, Verma S, et al. Miltefosine as an effective choice in the treatment of post‐kala‐azar dermal leishmaniasis. Br J Dermatol. 2011;165(2):411–414.
   PubMed Web of Science ®Google Scholar
• Sundar S, Sinha P, Jha TK, et al. Oral miltefosine for Indian post‐kala‐azar dermal leishmaniasis: a randomised trial. Trop Med Int Heal. 2013;18(1):96–100.
   PubMed Web of Science ®Google Scholar
• Dorlo TPC, van Thiel PPAM, Schoone GJ, et al. Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine. PLoS Negl Trop Dis. 2011;5(12):e1436.
   PubMed Web of Science ®Google Scholar
• Stojkovic M, Junghanss T, Krause E, et al. First case of typical Old World cutaneous leishmaniasis treated with miltefosine. Int J Dermatol. 2007;46(4):385–387.
   PubMed Web of Science ®Google Scholar
• Keynan Y, Larios OE, Wiseman MC, et al. Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan. Can J Infect Dis Med Microbiol. 2008;19(6):394–396.
   PubMed Web of Science ®Google Scholar
• Neub A, Krahl D, Stich A, et al. Cutaneous infection with Leishmania infantum in an infant treated successfully with miltefosine. J Dtsch Dermatol Ges. 2008;6(12):1061–1064.
   PubMed Web of Science ®Google Scholar
• Mohebali M, Fotouhi A, Hooshmand B, et al. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop. 2007;103(1):33–40.
   PubMed Web of Science ®Google Scholar
• Rubiano LC, Miranda MC, Muvdi Arenas S, et al. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. J Infect Dis. 2012;205(4):684–692.
   PubMed Web of Science ®Google Scholar
• Soto J, Arana BA, Toledo J, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis. 2004;38(9):1266–1272.
   PubMed Web of Science ®Google Scholar
• Soto J, Rea J, Balderrama M, et al. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg. 2008;78(2):210–211.
   PubMed Web of Science ®Google Scholar
• Machado PR, Ampuero J, Guimarães LH, et al. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis. 2010;4(12):e912.
   PubMed Web of Science ®Google Scholar
• Chrusciak-Talhari A, Dietze R, Talhari CC, et al. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. Am J Trop Med Hyg. 2011;84(2):255–260.
   PubMed Web of Science ®Google Scholar
• Soto J, Toledo J, Valda L, et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis. 2007;44(3):350–356.
   PubMed Web of Science ®Google Scholar
• Soto J, Rea J, Valderrama M, et al. Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia. Am J Trop Med Hyg. 2009;81(3):387–389.
   PubMed Web of Science ®Google Scholar
• Zerpa O, Ulrich M, Blanco B, et al. Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses. Br J Dermatol. 2007;156(6):1328–1335.
   PubMed Web of Science ®Google Scholar
• Zerpa O, Blanco B, Kannee C, et al. Treatment of diffuse cutaneous leishmaniasis with miltefosine: a case report. Int J Dermatol. 2006;45(6):751–753.
   PubMed Web of Science ®Google Scholar
• Ordaz-Farias A, Muñoz-Garza FZ, Sevilla-Gonzalez FK, et al. transient success using prolonged treatment with miltefosine for a patient with diffuse Cutaneous Leishmaniasis Infected with Leishmania mexicana mexicana. Am J Trop Med Hyg. 2013;88(1):153–156.
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J. Paromomycin in the treatment of leishmaniasis. Expert Opin Investig Drugs. 2008;17(5):787–794.
   PubMed Web of Science ®Google Scholar
• Jha TK, Lockwood DNJ, Olliaro P, et al. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, IndiaCommentary: some good news for treatment of visceral leishmaniasis in Bihar. Bmj. 1998;316(7139):1200–1205.
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP, et al. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med. 2007;356(25):2571–2581.
   PubMed Web of Science ®Google Scholar
• Sinha PK, Jha TK, Thakur CP, et al. Phase 4 pharmacovigilance trial of paromomycin injection for the treatment of visceral leishmaniasis in India. J Trop Med. 2011;2011:645203.
   PubMedGoogle Scholar
• Hailu A, Musa A, Wasunna M, et al. Geographical variation in the response of Visceral Leishmaniasis to Paromomycin in East Africa: a multicentre, open-label, randomized trial. Lockwood DNJ, editor. PLoS Negl Trop Dis [Internet]. 2010 Oct 26. 4(10):e709. [cited 2018 Dec 3]. DOI:10.1371/journal.pntd.0000709
   PubMed Web of Science ®Google Scholar
• Musa AM, Younis B, Fadlalla A, et al. Paromomycin for the treatment of Visceral Leishmaniasis in Sudan: a randomized, open-label, dose-finding study. Lockwood DNJ, editor. PLoS Negl Trop Dis [Internet]. 2010 Oct 26. 4(10):e855. [cited 2018 Dec 3]. DOI:10.1371/journal.pntd.0000855
   PubMed Web of Science ®Google Scholar
• Musa A, Khalil E, Hailu A, et al. Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: a randomised controlled trial. Lockwood DNJ, editor. PLoS Negl Trop Dis [Internet]. 2012 Jun 19. 6(6):e1674. [cited 2018 Dec 4]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22724029
   PubMed Web of Science ®Google Scholar
• Sundar S, Rai M. Treatment of visceral leishmaniasis. Expert Opin Pharmacother. 2005;6(16):2821–2829.
   PubMed Web of Science ®Google Scholar
• Soto J, Grogl M, Berman J, et al. Limited efficacy of injectable aminosidine as single-agent therapy for Colombian cutaneous leishmaniasis. Trans R Soc Trop Med Hyg. 1994;88(6):695–698.
   PubMed Web of Science ®Google Scholar
• Hepburn NC, Tidman MJ, Hunter JAA. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg. 1994;88(6):700–703.
   PubMed Web of Science ®Google Scholar
• Correia D, Macedo VO, Carvalho EM, et al. Comparative study of meglumine antimoniate, pentamidine isethionate and aminosidine sulfate in the treatment of primary skin lesions caused by Leishmania (Viannia) braziliensis. Rev Soc Bras Med Trop. 1996;29(5):447–453.
   PubMedGoogle Scholar
• Llanos-Cuentas A, Echevarria J, Seas C, et al. Parenteral aminosidine is not effective for Peruvian mucocutaneous leishmaniasis. Am J Trop Med Hyg. 2007;76(6):1128–1131.
   PubMed Web of Science ®Google Scholar
• Kim DH, Chung HJ, Bleys J, et al. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl Trop Dis. 2009;3(2):e381.
   PubMed Web of Science ®Google Scholar
• El-On J, Weinrauch L, Livshin R, et al. Topical treatment of recurrent cutaneous leishmaniasis with ointment containing paromomycin and methylbenzethonium chloride. Br Med J (Clin Res Ed). 1985;291(6497):704.
   PubMedGoogle Scholar
• El-On J, Livshin R, Even-Paz Z, et al. Topical treatment of cutaneous leishmaniasis. J Invest Dermatol. 1986;87(2):284–288.
   PubMed Web of Science ®Google Scholar
• El-On J, Halevy S, Grunwald MH, et al. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J Am Acad Dermatol. 1992;27(2):227–231.
   PubMed Web of Science ®Google Scholar
• Krause G, Kroeger A. Topical treatment of American cutaneous leishmaniasis with paramomycin and methylbenzethonium chloride: a clinical study under field conditions in Ecuador. Trans R Soc Trop Med Hyg. 1994;88(1):92–94.
   PubMed Web of Science ®Google Scholar
• Arana BA, Mendoza CE, Rizzo NR, et al. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg. 2001;65(5):466–470.
   PubMed Web of Science ®Google Scholar
• Asilian A, Jalayer T, Whitworth JAG, et al. A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg. 1995;53(6):648–651.
   PubMed Web of Science ®Google Scholar
• Salah AB, Zakraoui H, Zaatour A, et al. A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg. 1995;53(2):162–166.
   PubMed Web of Science ®Google Scholar
• Soto JM, Toledo JT, Gutierrez P, et al. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg. 2002;66(2):147–151.
   PubMed Web of Science ®Google Scholar
• Ben Salah A, Ben Messaoud N, Guedri E, et al. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med. 2013;368(6):524–532.
   PubMed Web of Science ®Google Scholar
• Sosa N, Capitán Z, Nieto J, et al. Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama. Am J Trop Med Hyg. 2013;89(3):557–563.
   PubMed Web of Science ®Google Scholar
• Soto J, Soto P, Ajata A, et al. Topical 15% Paromomycin-Aquaphilic for Bolivian Leishmania braziliensis Cutaneous Leishmaniasis: a randomized, placebo-controlled trial. Clin Infect Dis. 2019 Feb 15;68(5):844–849.
   PubMed Web of Science ®Google Scholar
• Pan American Health Organization. Leishmaniasis in the Americas: treatment recommendations.Washington, D.C.: PAHO; 2018. http://iris.paho.org.
   Google Scholar
• Jha SN, Singh NK, Jha TK. Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial. J Assoc Physicians India. 1991;39(4):314–316.
   PubMedGoogle Scholar
• Diro E, Ritmeijer K, Boelaert M, et al. Long-term clinical outcomes in visceral leishmaniasis/human immunodeficiency virus–coinfected patients during and after pentamidine secondary prophylaxis in Ethiopia: a single-arm clinical trial. Clin Infect Dis. 2017;66(3):444–451.
   Web of Science ®Google Scholar
• Paula CDRD, Sampaio JHD, Cardoso DR, et al. A comparative study between the efficacy of pentamidine isothionate given in three doses for one week and N-methil-glucamine in a dose of 20mgSbV/day for 20 days to treat cutaneous leishmaniasis. Rev Soc Bras Med Trop. 2003;36(3):365–371.
   PubMedGoogle Scholar
• Lai A Fat EJSK, Vrede MA, Soetosenojo RM, et al. Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam. Int J Dermatol. 2002;41(11):796–800.
   PubMed Web of Science ®Google Scholar
• Neves LO, Talhari AC, Gadelha EPN, et al. A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis. An Bras Dermatol. 2011;86(6):1092–1101.
   PubMed Web of Science ®Google Scholar
• Roussel M, Nacher M, Fremont G, et al. Comparison between one and two injections of pentamidine isethionate, at 7 mg/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol. 2006;100(4):307–314.
   PubMed Web of Science ®Google Scholar
• Soto J, Buffet P, Grogl M, et al. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am J Trop Med Hyg. 1994;50(1):107–111.
   PubMed Web of Science ®Google Scholar
• Christen J-R, Bourreau E, Demar M, et al. Use of the intramuscular route to administer pentamidine isethionate in Leishmania guyanensis cutaneous leishmaniasis increases the risk of treatment failure. Travel Med Infect Dis. 2018;24:31–36.
   PubMed Web of Science ®Google Scholar
• Soto J, Paz D, Rivero D, et al. Intralesional pentamidine: A novel therapy for single lesions of Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg. 2016;94(4):852–856.
   PubMed Web of Science ®Google Scholar
• Amato VS, Tuon FF, Imamura R, et al. Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil. J Eur Acad Dermatol Venereol. 2009;23(9):1026–1034.
   PubMed Web of Science ®Google Scholar
• Jha TK, Sundar S, Thakur CP, et al. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am J Trop Med Hyg. 2005;73(6):1005–1011.
   PubMed Web of Science ®Google Scholar
• Sundar S, Sinha PK, Dixon SA, et al. Pharmacokinetics of oral sitamaquine taken with or without food and safety and efficacy for treatment of visceral leishmaniais: a randomized study in Bihar, India. Am J Trop Med Hyg. 2011;84(6):892–900.
   PubMed Web of Science ®Google Scholar
• Wasunna MK, Rashid JR, Mbui J, et al. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. Am J Trop Med Hyg. 2005;73(5):871–876.
   PubMed Web of Science ®Google Scholar
• Alrajhi AA, Ibrahim EA, De Vol EB, et al. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med. 2002;346(12):891–895.
   PubMed Web of Science ®Google Scholar
• Morizot G, Delgiudice P, Caumes E, et al. Healing of Old World cutaneous leishmaniasis in travelers treated with fluconazole: drug effect or spontaneous evolution? Am J Trop Med Hyg. 2007;76(1):48–52.
   PubMed Web of Science ®Google Scholar
• Emad M, Hayati F, Fallahzadeh MK, et al. Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: a randomized clinical trial. J Am Acad Dermatol. 2011;64(3):606–608.
   PubMed Web of Science ®Google Scholar
• Sousa AQ, Frutuoso MS, Moraes EA, et al. High-dose oral fluconazole therapy effective for cutaneous leishmaniasis due to Leishmania (Vianna) braziliensis. Clin Infect Dis. 2011;53(7):693–695.
   PubMed Web of Science ®Google Scholar
• Prates FVDO, Dourado MEF, Silva SC, et al. Fluconazole in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis : a randomized controlled trial. Clin Infect Dis Internet]. 2017 Jan 1. 64(1):67–71. [cited 2018 Dec 4]. Available from: https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/ciw662
   PubMed Web of Science ®Google Scholar
• Dogra J, Saxena VN. Itraconazole and leishmaniasis: a randomised double-blind trial in cutaneous disease. Int J Parasitol. 1996;26(12):1413–1415.
   PubMed Web of Science ®Google Scholar
• Momeni AZ, Jalayer T, Emamjomeh M, et al. Treatment of cutaneous leishmaniasis with itraconazole: randomized double-blind study. Arch Dermatol. 1996;132(7):784–786.
   PubMedGoogle Scholar
• Nassiri‐Kashani M, Firooz A, Khamesipour A, et al. A randomized, double‐blind, placebo‐controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis. J Eur Acad Dermatol Venereol. 2005;19(1):80–83.
   PubMed Web of Science ®Google Scholar
• Soto-Mancipe J, Grogl M, Berman JD. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis. 1993;16(3):417–425.
   PubMed Web of Science ®Google Scholar
• Amato VS, Padilha ARS, Nicodemo AC, et al. Use of itraconazole in the treatment of mucocutaneous leishmaniasis: a pilot study. Int J Infect Dis. 2000;4(3):153–157.
   PubMedGoogle Scholar
• Calvopina M, Guevara AG, Armijos RX, et al. Itraconazole in the treatment of New World mucocutaneous leishmaniasis. Int J Dermatol. 2004;43(9):659–663.
   PubMed Web of Science ®Google Scholar
• Salmanpour MK, Nouhpisheh RFH. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis. J Dermatolog Treat. 2001;12(3):159–162.
   PubMed Web of Science ®Google Scholar
• Alsaleh QA, Dvorak R, Nanda A. Ketoconazole in the treatment of cutaneous leishmaniasis in Kuwait. Int J Dermatol. 1995;34(7):495–497.
   PubMed Web of Science ®Google Scholar
• Ozgoztasi O, Baydar I. A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey. Int J Dermatol. 1997;36(1):61–63.
   PubMed Web of Science ®Google Scholar
• Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med. 1990;89(2):147–155.
   PubMed Web of Science ®Google Scholar
• Navin TR, Arana BA, Arana FE, et al. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis. 1992;165(3):528–534.
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J. Investigational drugs for visceral leishmaniasis. Expert Opin Investig Drugs. 2015;24(1):43–59.
   PubMed Web of Science ®Google Scholar
• Mesu VKBK, Kalonji WM, Bardonneau C, et al. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet. 2018;391(10116):144–154.
   PubMed Web of Science ®Google Scholar
• Wyllie S, Patterson S, Stojanovski L, et al. The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis. Sci Transl Med. 2012;4(119):119re1–119re1.
   PubMed Web of Science ®Google Scholar
• Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan - Full Text View - ClinicalTrials.gov [Internet]. [cited 2018 Sept 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT01980199
   Google Scholar
• Fexinidazole/Miltefosine Combination (VL) – DNDi [Internet]. [cited 2018 Sept 6]. Available from: https://www.dndi.org/diseases-projects/portfolio/completed-projects/fexinidazole-vl/
   Google Scholar
• Dawson R, Diacon AH, Everitt D, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul. Lancet. 2015;385(9979):1738–1747.
   PubMed Web of Science ®Google Scholar
• Patterson S, Wyllie S, Stojanovski L, et al. The R enantiomer of the anti-tubercular drug PA-824 as a potential oral treatment for visceral leishmaniasis. Antimicrob Agents Chemother. 2013;57(10):4699–4706.
   Web of Science ®Google Scholar
• Patterson S, Wyllie S, Norval S, et al. The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis. Elife. 2016;5:e09744.
   PubMed Web of Science ®Google Scholar
• Reithinger R, Mohsen M, Wahid M, et al. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin Infect Dis. 2005;40(8):1148–1155.
   PubMed Web of Science ®Google Scholar
• Safi N, Davis GD, Nadir M, et al. Evaluation of thermotherapy for the treatment of cutaneous leishmaniasis in Kabul, Afghanistan: a randomized controlled trial. Mil Med. 2012;177(3):345–351.
   PubMed Web of Science ®Google Scholar
• Bumb RA, Prasad N, Khandelwal K, et al. Long‐term efficacy of single‐dose radiofrequency‐induced heat therapy vs. intralesional antimonials for cutaneous leishmaniasis in India. Br J Dermatol. 2013;168(5):1114–1119.
   PubMed Web of Science ®Google Scholar
• Aronson NE, Wortmann GW, Byrne WR, et al. A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection. PLoS Negl Trop Dis. 2010;4(3):e628.
   PubMed Web of Science ®Google Scholar
• Sadeghian G, Nilfroushzadeh MA, Iraji F. Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate. Clin Exp Dermatol. 2007;32(4):371–374.
   PubMed Web of Science ®Google Scholar
• Velasco-Castrejon O, Walton BC, Rivas-Sanchez B, et al. Treatment of cutaneous leishmaniasis with localized current field (radio frequency) in Tabasco, Mexico. Am J Trop Med Hyg. 1997;57(3):309–312.
   PubMed Web of Science ®Google Scholar
• López L, Robayo M, Vargas M, et al. Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis. Trials. 2012;13(1):58.
   PubMedGoogle Scholar
• López L, Cruz C, Godoy G, et al. Thermoterapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in Colombia. Rev Inst Med Trop Sao Paulo. 2013;55(3):197–204.
   Web of Science ®Google Scholar
• Valencia BM, Miller D, Witzig RS, et al. Novel low-cost thermotherapy for cutaneous leishmaniasis in Peru. PLoS Negl Trop Dis. 2013;7(5):e2196.
   PubMed Web of Science ®Google Scholar
• Cardona-Arias JA, Vélez ID, López-Carvajal L. Efficacy of thermotherapy to treat cutaneous leishmaniasis: a meta-analysis of controlled clinical trials. PLoS One. 2015;10(5):e0122569.
   PubMed Web of Science ®Google Scholar
• Leibovici V, Aram H. Cryotherapy in acute cutaneous leishmaniasis. Int J Dermatol. 1986;25(7):473–475.
   PubMed Web of Science ®Google Scholar
• Mosleh IM, Geith E, Natsheh L, et al. Efficacy of a weekly cryotherapy regimen to treat Leishmania major cutaneous leishmaniasis. J Am Acad Dermatol. 2008;58(4):617–624.
   PubMed Web of Science ®Google Scholar
• Al‐Majali O, Routh HB, Abuloham O, et al. A 2‐year study of liquid nitrogen therapy in cutaneous leishmaniasis. Int J Dermatol. 1997;36(6):460–462.
   PubMed Web of Science ®Google Scholar
• Panagiotopoulos A, Stavropoulos PG, Hasapi V, et al. Treatment of cutaneous leishmaniasis with cryosurgery. Int J Dermatol. 2005;44(9):749–752.
   PubMed Web of Science ®Google Scholar
• Gurei MS, Tatli N, Ozbilge H, et al. Efficacy of cryotherapy and intralesional pentostam in treatment of cutaneous leishmaniasis. J Egypt Soc Parasitol. 2000;30(1):169–176.
   PubMedGoogle Scholar
• Negera E, Gadisa E, Hussein J, et al. Treatment response of cutaneous leishmaniasis due to Leishmania aethiopica to cryotherapy and generic sodium stibogluconate from patients in Silti, Ethiopia. Trans R Soc Trop Med Hyg. 2012;106(8):496–503.
   PubMed Web of Science ®Google Scholar
• Ranawaka RR, Weerakoon HS, Opathella N. Liquid nitrogen cryotherapy on Leishmania donovani cutaneous leishmaniasis. J Dermatolog Treat. 2011;22(4):241–245.
   PubMed Web of Science ®Google Scholar
• Soto J, Rojas E, Guzman M, et al. Intralesional antimony for single lesions of bolivian cutaneous leishmaniasis. Clin Infect Dis. 2013;56(9):1255–1260.
   PubMed Web of Science ®Google Scholar
• López-Carvajal L, Cardona-Arias JA, Zapata-Cardona MI, et al. Efficacy of cryotherapy for the treatment of cutaneous leishmaniasis: meta-analyses of clinical trials. BMC Infect Dis. 2016;16(1):360.
   PubMedGoogle Scholar
• Nassif PW, De Mello TFP, Navasconi TR, et al. Safety and efficacy of current alternatives in the topical treatment of cutaneous leishmaniasis: a systematic review. Parasitology. 2017;144(8):995–1004.
   PubMed Web of Science ®Google Scholar
• Asilian A, Sharif A, Faghihi G, et al. Evaluation of CO2 laser efficacy in the treatment of cutaneous leishmaniasis. Int J Dermatol. 2004;43(10):736–738.
   PubMed Web of Science ®Google Scholar
• Shamsi Meymandi S, Zandi S, Aghaie H, et al. Efficacy of CO2 laser for treatment of anthroponotic cutaneous leishmaniasis, compared with combination of cryotherapy and intralesional meglumine antimoniate. J Eur Acad Dermatol Venereol. 2011;25(5):587–591.
   PubMed Web of Science ®Google Scholar
• Rodriguez ME, Inguanzo P, Ramos A, et al. Treatment of cutaneous leishmaniasis with CO2 laser radiation. Rev Cubana Med Trop. 1990;42(2):197–202.
   PubMedGoogle Scholar
• Chunge CN, Owate J, Pamba HO, et al. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg. 1990;84(2):221–225.
   PubMed Web of Science ®Google Scholar
• Seaman J, Pryce D, Sondorp HE, et al. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J Infect Dis. 1993;168(3):715–720.
   PubMed Web of Science ®Google Scholar
• Melaku Y, Collin SM, Keus K, et al. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am J Trop Med Hyg. 2007;77(1):89–94.
   PubMed Web of Science ®Google Scholar
• Thakur CP, Olliaro P, Gothoskar S, et al. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg. 1992;86(6):615–616.
   PubMed Web of Science ®Google Scholar
• Thakur CP, Kanyok TP, Pandey AK, et al. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg. 2000;94(4):429–431.
   PubMed Web of Science ®Google Scholar
• Kimutai R, Musa AM, Njoroge S, et al. Safety and effectiveness of sodium stibogluconate and paromomycin combination for the treatment of visceral leishmaniasis in Eastern Africa: results from a pharmacovigilance programme. Clin Drug Investig. 2017;37(3):259–272.
   PubMed Web of Science ®Google Scholar
• Seifert K, Croft SL. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob Agents Chemother. 2006;50(1):73–79.
   PubMed Web of Science ®Google Scholar
• Sundar S, Rai M, Chakravarty J, et al. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis. 2008;47(8):1000–1006.
   PubMed Web of Science ®Google Scholar
• Sundar S, Sinha PK, Rai M, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet. 2011;377(9764):477–486.
   PubMed Web of Science ®Google Scholar
• Rahman R, Goyal V, Haque R, et al. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh. PLoS Negl Trop Dis. 2017;11(5):e0005635.
   PubMed Web of Science ®Google Scholar
• Goyal V, Mahajan R, Pandey K, et al. Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India. PLoS Negl Trop Dis. 2018;12(10):e0006830.
   PubMed Web of Science ®Google Scholar
• Wasunna M, Njenga S, Balasegaram M, et al. Efficacy and safety of AmBisome in combination with sodium stibogluconate or miltefosine and miltefosine monotherapy for African visceral leishmaniasis: phase II randomized trial. PLoS Negl Trop Dis. 2016;10(9):e0004880.
   PubMed Web of Science ®Google Scholar
• Romero GAS, Costa DL, Costa CHN, et al. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: a multicenter, randomized, open label trial. PLoS Negl Trop Dis. 2017;11(6):e0005706.
   PubMed Web of Science ®Google Scholar
• Mahajan R, Das P, Isaakidis P, et al. Combination treatment for visceral leishmaniasis patients coinfected with human immunodeficiency virus in India. Clin Infect Dis. 2015;61(8):1255–1262.
   PubMed Web of Science ®Google Scholar
• Abongomera C, Diro E, de Lima Pereira A, et al. The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: a retrospective cohort study. PLoS Negl Trop Dis. 2018;12(5):e0006527.
   PubMed Web of Science ®Google Scholar
• Machado PRL, Lessa H, Lessa M, et al. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis. 2007;44(6):788–793.
   PubMed Web of Science ®Google Scholar
• Sadeghian G, Nilforoushzadeh MA. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis. Int J Dermatol. 2006;45(7):819–821.
   PubMed Web of Science ®Google Scholar
• Momeni AZ, Reiszadae MR, Aminjavaheri M. Treatment of cutaneous leishmaniasis with a combination of allopurinol and low‐dose meglumine antimoniate. Int J Dermatol. 2002;41(7):441–443.
   PubMed Web of Science ®Google Scholar
• El Darouti MA, Al Rubaie SM. Cutaneous leishmaniasis: treatment with combined cryotherapy and intralesional stibogluconate injection. Int J Dermatol. 1990;29(1):56–59.
   PubMed Web of Science ®Google Scholar
• Asilian A, Sadeghinia A, Faghihi G, et al. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis. Ann Trop Med Parasitol. 2003;97(5):493–498.
   PubMed Web of Science ®Google Scholar
• Jaffary F, Nilforoushzadeh MA, Siadat A, et al. A comparison between the effects of glucantime, topical trichloroacetic acid 50% plus glucantime, and fractional carbon dioxide laser plus glucantime on cutaneous leishmaniasis lesions. Dermatol Res Pract. 2016;2016:Article ID 6462804. DOI:10.1155/2016/6462804.
   Web of Science ®Google Scholar
• Soto J, Soto P, Ajata A, et al. Miltefosine Combined with Intralesional Pentamidine for Leishmania braziliensis Cutaneous Leishmaniasis in Bolivia. Am J Trop Med Hyg. 2018.
   PubMed Web of Science ®Google Scholar
• Soto J, Hernandez N, Mejia H, et al. Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate. Clin Infect Dis. 1995;20(1):47–51.
   PubMed Web of Science ®Google Scholar
• Soto J, Fuya P, Herrera R, et al. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clin Infect Dis. 1998;26(1):56–58.
   PubMed Web of Science ®Google Scholar
• Miltefosine/Paromomycin Combination for Africa – DNDi [Internet]. [ cited 2018 Nov 11]. Available from: https://www.dndi.org/diseases-projects/portfolio/miltefosine-paromomycin-combo/
   Google Scholar
• Organization WH. Kala-Azar elimination programme: report of a WHO consultation of partners, Geneva, Switzerland: World Health Organization; 2015. [2015 Feb 10-11].
   Google Scholar
• New Treatments for PKDL – DNDi [Internet]. [ cited 2018 Nov 11]. Available from: https://www.dndi.org/diseases-projects/portfolio/pkdl-2/
   Google Scholar
• Diro E, Blesson S, Edwards T, et al. A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia. PLoS Negl Trop Dis. 2019;13(1):e0006988.
   PubMed Web of Science ®Google Scholar